TriangleNCT01445080 · OUTCOME
Plasma Inhibitory Activity (PIA)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 1 week prior to enrollment and then every 28 days
What was measured
Analyze the plasma inhibitory activity (PIA) for FLT3 phosphorylation in peripheral blood samples obtained at the time of PK studies in patients with FLT3-ITD mutation AML (Part C).
Groups in this outcome
Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2
Patients receive oral sorafenib 150 mg/m\^2 every 12 hours.
| Group | Source count |
|---|---|
| Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2 | 5 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2 | 5 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 5
- denoms
- counts
- group Id
- OG000
- value
- 5
- units
- Participants
- description
- Analyze the plasma inhibitory activity (PIA) for FLT3 phosphorylation in peripheral blood samples obtained at the time of PK studies in patients with FLT3-ITD mutation AML (Part C).
- groups
- description
- Patients receive oral sorafenib 150 mg/m\^2 every 12 hours.
- id
- OG000
- title
- Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- 1 week prior to enrollment and then every 28 days
- title
- Plasma Inhibitory Activity (PIA)
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice